Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals European Union - English - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from a/vietnam/1194/2004 nibrg-14 (h5n1) (see section 5.1).prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals 3.75 µg should be used in accordance with official guidance.

COVID-19 Vaccine (inactivated, adjuvanted) Valneva European Union - English - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccines - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.

Inactivated Rabies Vaccine Merieux HDCV inj. sol. (pwdr. + solv.) i.m. vial + pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

inactivated rabies vaccine merieux hdcv inj. sol. (pwdr. + solv.) i.m. vial + pre-filled syr.

sanofi pasteur europe s.a. - rabies virus (inactivated) ; albumin human 50 mg - powder and solvent for solution for injection - rabies virus, inactivated - rabies, inactivated, whole virus

AP125RX Inactivated Actinobacillus pleuropneumoniae (Total bacterial count) 41-1 strain (serotype 1) (seed), SHP-1 strain 9serotype 2) (seed), Ng-2 strain (serotype 5) (seed)- 1.0x10^9 ~5.0x10^9 cells each; Non-toxigenic cytotoxic cytotoxins of Actinobacillus pleuropneumoniae (derived from recombinant Escherichia coli) rApx I Protein (seed), rApx II protein (seed), rApx III Protein (seed) - 80-120 mcg each Suspension for Injection (IN Philippines - English - FDA (Food And Drug Administration)

ap125rx inactivated actinobacillus pleuropneumoniae (total bacterial count) 41-1 strain (serotype 1) (seed), shp-1 strain 9serotype 2) (seed), ng-2 strain (serotype 5) (seed)- 1.0x10^9 ~5.0x10^9 cells each; non-toxigenic cytotoxic cytotoxins of actinobacillus pleuropneumoniae (derived from recombinant escherichia coli) rapx i protein (seed), rapx ii protein (seed), rapx iii protein (seed) - 80-120 mcg each suspension for injection (in

superiorvet inc.; distributor: superiorvet inc. - inactivated actinobacillus pleuropneumoniae vaccine (vet.) - suspension for injection (in - inactivated actinobacillus pleuropneumoniae (total bacterial count) 41-1 strain (serotype 1) (seed), shp-1 strain 9serotype 2) (seed), ng-2 strain (serotype 5) (seed)- 1.0x10^9 ~5.0x10^9 cells each; non-toxigenic cytotoxic cytotoxins of actinobacillus pleuropneumoniae (derived from recombinant escherichia coli) rapx i protein (seed), rapx ii protein (seed), rapx iii protein (seed) - 80-120 mcg each

AVISAN SECURE INACTIVATED SALMONELLA ENTERITIDIS ? 1/13 +   INACTIVATED SALMONELLA TYPHIMURIUM   ? 1/40 PARENTERAL ORDINARY VIAL Uganda - English - National Drug Authority

avisan secure inactivated salmonella enteritidis ? 1/13 + inactivated salmonella typhimurium ? 1/40 parenteral ordinary vial

laboratorios hipra s.a - inactivated salmonella enteritidis pt-4 fagotype mat + inactivated salmonella typhimurium, dt-4 fagotype mat - parenteral ordinary vials - inactivated salmonella enteritidis ? 1/13 + inactivated salmonella typhimurium ? 1/40